C57BL/6JCya-Edem2em1/Cya
Common Name
Edem2-KO
Product ID
S-KO-00608
Backgroud
C57BL/6JCya
Strain ID
KOCMP-108687-Edem2-B6J-VA
Status
When using this mouse strain in a publication, please cite “Edem2-KO Mouse (Catalog S-KO-00608) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
Basic Information
Strain Name
Edem2-KO
Strain ID
KOCMP-108687-Edem2-B6J-VA
Gene Name
Product ID
S-KO-00608
Gene Alias
9530090G24Rik
Background
C57BL/6JCya
NCBI ID
Modification
Conventional knockout
Chromosome
Chr 2
Phenotype
Datasheet
Application
--
Strain Description
Ensembl Number
ENSMUST00000040833
NCBI RefSeq
NM_145537
Target Region
Exon 4~7
Size of Effective Region
~10.5 kb
Overview of Gene Research
Edem2, also known as endoplasmic reticulum degradation-enhancing alpha-mannosidase-like protein 2, is a key protein in the endoplasmic reticulum-associated degradation (ERAD) pathway. It is involved in the selection and degradation of misfolded proteins from the endoplasmic reticulum. Specifically, it plays a role in the mannose trimming of N-glycan in the ERAD of misfolded glycoproteins, which is crucial for maintaining endoplasmic reticulum homeostasis [2,4,5].
In a mouse model, Edem2 knockdown led to lipid droplet accumulation, higher levels of triglycerides and diglycerides in the myocardium, aggravating oxidative stress, hypertrophy, and the onset and progression of heart failure with preserved ejection fraction (HFpEF) under metabolic stress. This indicates that Edem2 is important in regulating cardiac lipid homeostasis [1]. In glioma cells, the knockdown of Edem2 decreased their invasive ability, suggesting its role in glioma cell invasion [3].
In conclusion, Edem2 is essential for ER-associated degradation processes, especially in mannose trimming of misfolded glycoproteins. The use of gene-knockout models, such as in mice and cell-based knockdown studies, has revealed its significant roles in diseases like HFpEF and glioma, highlighting its potential as a therapeutic target in these disease areas.
References:
1. Fonseka, Oveena, Raja, Rida, Ross, Claire, Müller, Oliver J, Liu, Wei. 2025. XBP1s-EDEM2 Prevents the Onset and Development of HFpEF by Ameliorating Cardiac Lipotoxicity. In Circulation, , . doi:10.1161/CIRCULATIONAHA.124.072194. https://pubmed.ncbi.nlm.nih.gov/40130322/
2. George, Ginto, Ninagawa, Satoshi, Yagi, Hirokazu, Okada, Tetsuya, Mori, Kazutoshi. 2020. EDEM2 stably disulfide-bonded to TXNDC11 catalyzes the first mannose trimming step in mammalian glycoprotein ERAD. In eLife, 9, . doi:10.7554/eLife.53455. https://pubmed.ncbi.nlm.nih.gov/32065582/
3. Wu, Yuxi, Wang, Haofei, Xiang, Wei, Yi, Dongye. 2023. EDEM2 is a diagnostic and prognostic biomarker and associated with immune infiltration in glioma: A comprehensive analysis. In Frontiers in oncology, 12, 1054012. doi:10.3389/fonc.2022.1054012. https://pubmed.ncbi.nlm.nih.gov/36727065/
4. Olivari, Silvia, Molinari, Maurizio. 2007. Glycoprotein folding and the role of EDEM1, EDEM2 and EDEM3 in degradation of folding-defective glycoproteins. In FEBS letters, 581, 3658-64. doi:. https://pubmed.ncbi.nlm.nih.gov/17499246/
5. Ninagawa, Satoshi, Okada, Tetsuya, Sumitomo, Yoshiki, Yamamoto, Takashi, Mori, Kazutoshi. . EDEM2 initiates mammalian glycoprotein ERAD by catalyzing the first mannose trimming step. In The Journal of cell biology, 206, 347-56. doi:10.1083/jcb.201404075. https://pubmed.ncbi.nlm.nih.gov/25092655/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
